Cargando…

Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel

Resistant bacteria limit treatment options. This challenge has awakened interest in antibiotics that are no longer in use due to side effects, such as chloramphenicol. This work investigated trends in chloramphenicol resistance rates during 2017–2020 in bacteria isolated from diverse clinical sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohana, Hannan, Hager-Cohen, Anat, Azrad, Maya, Peretz, Avi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952794/
https://www.ncbi.nlm.nih.gov/pubmed/36830107
http://dx.doi.org/10.3390/antibiotics12020196
_version_ 1784893720167972864
author Rohana, Hannan
Hager-Cohen, Anat
Azrad, Maya
Peretz, Avi
author_facet Rohana, Hannan
Hager-Cohen, Anat
Azrad, Maya
Peretz, Avi
author_sort Rohana, Hannan
collection PubMed
description Resistant bacteria limit treatment options. This challenge has awakened interest in antibiotics that are no longer in use due to side effects, such as chloramphenicol. This work investigated trends in chloramphenicol resistance rates during 2017–2020 in bacteria isolated from diverse clinical samples at the Baruch Padeh Medical Center, Poriya, Israel. Bacteria were isolated from 3873 samples and identified using routine methods, including matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) technology. Chloramphenicol susceptibility was tested using a VITEK II instrument or by the Kirby–Bauer disk-diffusion test. The average chloramphenicol resistance rate was 24%, with no significant differences between study years. Chloramphenicol resistance was associated with sample origin (p < 0.001); isolates originating from sputum samples showed 49.8% resistance rate, compared to 2.3% of the body fluid isolates, 10.4% of the ear/eye isolates and 22.5% of the blood isolates. Furthermore, there was a significant decrease in chloramphenicol resistance among blood and ear/eye isolates during the study period (p = 0.01, p < 0.001, respectively). The highest resistance rate was among Pseudomonas aeruginosa isolates (50.5%). In conclusion, since chloramphenicol susceptibility seems to be retained, its comeback to the clinical world should be considered.
format Online
Article
Text
id pubmed-9952794
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99527942023-02-25 Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel Rohana, Hannan Hager-Cohen, Anat Azrad, Maya Peretz, Avi Antibiotics (Basel) Communication Resistant bacteria limit treatment options. This challenge has awakened interest in antibiotics that are no longer in use due to side effects, such as chloramphenicol. This work investigated trends in chloramphenicol resistance rates during 2017–2020 in bacteria isolated from diverse clinical samples at the Baruch Padeh Medical Center, Poriya, Israel. Bacteria were isolated from 3873 samples and identified using routine methods, including matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) technology. Chloramphenicol susceptibility was tested using a VITEK II instrument or by the Kirby–Bauer disk-diffusion test. The average chloramphenicol resistance rate was 24%, with no significant differences between study years. Chloramphenicol resistance was associated with sample origin (p < 0.001); isolates originating from sputum samples showed 49.8% resistance rate, compared to 2.3% of the body fluid isolates, 10.4% of the ear/eye isolates and 22.5% of the blood isolates. Furthermore, there was a significant decrease in chloramphenicol resistance among blood and ear/eye isolates during the study period (p = 0.01, p < 0.001, respectively). The highest resistance rate was among Pseudomonas aeruginosa isolates (50.5%). In conclusion, since chloramphenicol susceptibility seems to be retained, its comeback to the clinical world should be considered. MDPI 2023-01-18 /pmc/articles/PMC9952794/ /pubmed/36830107 http://dx.doi.org/10.3390/antibiotics12020196 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Rohana, Hannan
Hager-Cohen, Anat
Azrad, Maya
Peretz, Avi
Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel
title Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel
title_full Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel
title_fullStr Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel
title_full_unstemmed Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel
title_short Trend of Changes in Chloramphenicol Resistance during the Years 2017–2020: A Retrospective Report from Israel
title_sort trend of changes in chloramphenicol resistance during the years 2017–2020: a retrospective report from israel
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952794/
https://www.ncbi.nlm.nih.gov/pubmed/36830107
http://dx.doi.org/10.3390/antibiotics12020196
work_keys_str_mv AT rohanahannan trendofchangesinchloramphenicolresistanceduringtheyears20172020aretrospectivereportfromisrael
AT hagercohenanat trendofchangesinchloramphenicolresistanceduringtheyears20172020aretrospectivereportfromisrael
AT azradmaya trendofchangesinchloramphenicolresistanceduringtheyears20172020aretrospectivereportfromisrael
AT peretzavi trendofchangesinchloramphenicolresistanceduringtheyears20172020aretrospectivereportfromisrael